Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV9-CCL4
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
AAV9-CCL4 is an adeno-associated virus serotype 9 (AAV9) gene therapy vector designed to express the chemokine (C-C motif) ligand 4 (CCL4). Developed by researchers at the University of California, San Francisco (UCSF), it is administered via convection-enhanced delivery (CED) directly into the brain to treat glioblastoma. The therapeutic strategy involves using CCL4 to reprogram the immunosuppressive glioblastoma microenvironment by recruiting and activating anti-tumor immune cells, such as macrophages and CD8+ T cells. Preclinical studies have demonstrated that AAV9-CCL4 can suppress pro-tumor cytokines like IL-6 and LIF, potentially sensitizing "cold" tumors to immune checkpoint inhibition.
- Other names
- AAV9-Ccl4AAV-9-Ccl4AAV 9-Ccl4
02
Targets
CCR5 (C-C chemokine receptor type 5)AAVR/Gal (Adeno-associated virus receptor (AAVR) and terminal galactose glycans)
Beyond the preview
Go deeper on AAV9-CCL4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV9-CCL4.